Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
Public ClinicalTrials.gov record NCT02425111. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.
Study identification
- NCT ID
- NCT02425111
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2015 (Actual)
- Primary completion
- Jun 2, 2017 (Actual)
- Completion
- Feb 21, 2018 (Actual)
- Last update posted
- Sep 14, 2018
2015 – 2018
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | La Jolla | California | — | — |
| Not listed | Hamden | Connecticut | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Inverness | Florida | — | — |
| Not listed | Maitland | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Winter Park | Florida | — | — |
| Not listed | Macon | Georgia | — | — |
| Not listed | Suwanee | Georgia | — | — |
| Not listed | Topeka | Kansas | — | — |
| Not listed | Baton Rouge | Louisiana | — | — |
| Not listed | Columbia | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Manhasset | New York | — | — |
| Not listed | Poughkeepsie | New York | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Germantown | Tennessee | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02425111, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2018 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02425111 live on ClinicalTrials.gov.